32.31
-2.11 (-6.13%)
| Previous Close | 34.42 |
| Volume | 75,671 |
| Price / Sales | 2.90 |
| Price / Book | 2.27 |
| 52 Weeks Range |
| Profit Margin | -1.46% |
| Operating Margin (TTM) | -31.74% |
| Diluted EPS (TTM) | -0.190 |
| Quarterly Revenue Growth (YOY) | 20.60% |
| Total Debt/Equity (MRQ) | 5.87% |
| Current Ratio (MRQ) | 9.37 |
| Operating Cash Flow (TTM) | 65.67 M |
| Levered Free Cash Flow (TTM) | 44.64 M |
| Return on Assets (TTM) | -1.80% |
| Return on Equity (TTM) | -1.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Castle Biosciences, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -0.88 |
Select this tab to load the latest available analysis.
|
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 2.98% |
| % Held by Institutions | 93.02% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Summit Partners Public Asset Management, Llc | 30 Jun 2026 | 824,872 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MAETZOLD DEREK J | - | 36.65 | -14,496 | -531,278 |
| Aggregate Net Quantity | -14,496 | |||
| Aggregate Net Value ($) | -531,278 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 36.65 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Officer | 05 Oct 2026 | Automatic sell (-) | 8,580 | 36.65 | 314,457 |
| MAETZOLD DEREK J | Officer | 05 Oct 2026 | Automatic sell (-) | 5,916 | 36.65 | 216,821 |
| MAETZOLD DEREK J | Officer | 05 Oct 2026 | Option execute | 8,165 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |